Discover the newest ingredients /customized formulation: 
Insumate®: Patented bitter melon peptide (mcIRBP-19)
Antromax®: Patented Antrodia Cinnamomea

The best-selling Bitter Melon Extract from Greenyn Biotechnology (6846) is celebrating more success. After winning the South Korean World Invention Innovation Contest WiC, it won the AII American Da Vinci International Innovation and Invention Expo, receiving international fame. This achievement supports Taiwanese brand clients expanding globally.

Right After Greenyn Biotechnology (6846) was listed on the Taiwan Stock Exchange. On 5/19, Greenyn Biotechnology won 2 gold medals from Tokyo World Genius Convention and Expedition Expo 2023 with is self-developed native plant extract including Crassocephalum rabens extract (RabenWhite® and RabenLiv®) and Antrodia cinnammomea mycelia (Antromax®).

Taipei, Taiwan – Greenyn Biotechnology (6846) is proud to announce that its exclusive "Insumate® Patented Amino Peptide Sequence mcIRBP-19" bitter melon extract has received approval from the United States Food and Drug Administration (FDA) as a New Dietary Ingredient (NDI). This significant achievement comes after 12 years of dedicated research and collaboration with prestigious medical institutions in Taiwan.

Taipei, Taiwan – Greenyn Biotechnology (6846), in collaboration with the National Research Institute, has spent over a decade in the development of patented plant extract materials, RabenLiv® and RabenWhite®. These outstanding innovations were recognized at the International Symposium on Food and Health for Long Covid on March 10th, where they were presented with the " Health Supplement Innovation Award". This accolade reaffirms the high quality of Greenyn Biotechnology’s research outcomes.

Greenyn Biotechnology (6846) is pleased to announce that its health supplement ingredient brand, "Antromax® Antrodia Cinnammomea Mycelia," has been awarded the 2022 "SNQ National Quality Label" by the Taiwan Institute for Biotechnology and Medicine Industry (IBMI). Greenyn Biotechnology expressed its gratitude for this national-level recognition, which reflects the practical benefits and high-quality safety standards of this ingredient.

"Insumate® Patented Amino Peptide Sequencing mcIRBP-19" is the only bitter melon extract that has undergone two large-scale clinical trials after more than 12 years of research conducted by Greenyn Biotechnology's (6846) R&D team in collaboration with Taiwan's leading medical institutions, and has been awarded the 19th National Innovation Award - Enterprise Innovation Award for 2022.

We sincerely invite you to attend SupplySide WEST 2022. In this show, we will exhibit our innovative and proprietary ingredients.

We sincerely invite you to attend Vitafoods Asia 2022. In this show, we will exhibit our innovative and proprietary ingredients.

Taiwan’s biotech is gradually emerging. During the COVID-19 epidemic, we had a chance to see the advanced medical equipment and the effective preventive measures taken at the community level.

Greenyn Biotechnology received USFDA NDI acknowledgement without objection for Antrodia cinnamomea mycelia "Antromax"

綠茵生技捷報連連，榮獲台灣生物產業發展協會舉辦的『2021 Taiwan BIO Awards傑出生技產業獎』之「潛力標竿獎」，營運及創新研發能力深獲肯定，在穩健踏實的成長下，公開發行亦已於7月21日生效，邁入新的里程碑。

國家磐石獎：11家傑出企業榮獲。海外台商磐石獎：8家脫穎而出。頒獎典禮齊聚一堂，同享喜悅及榮耀。

綠茵生技榮獲第30屆「國家磐石獎」殊榮，日前假台北君悅酒店舉行頒獎典禮，由蔡英文總統親臨頒獎祝賀，並嘉勉得獎企業不僅代表中小企業最高榮耀，也身負中小企業卓越典範的使命。

綠茵生技榮獲「2021 Taiwan BIO Awards傑出生技產業獎」之「潛力標竿獎」，於11月4日「BIO Asia-Taiwan 2021亞洲生技大展實體展」中，由前副總統陳建仁院士授獎，代表綠茵生技在研發能量及未來發展的潛力、促進台灣生技產業升級及經濟發展的貢獻獲得高度肯定。

綠茵生技已於今年7月正式公開發行，今年將偕同子公司-康普森生技，以綠茵集團之姿一同參與亞洲美容保養暨生技保健展。

綠茵獲生技產業-潛力標竿獎 一站式攜客戶闖國際

綠茵生技於2021年初獲得美國FDA NDI核准上市，成為全球首家獲得NDI的牛樟芝研發公司!

國際首例牛樟芝產品獲美國FDA認證 帶動台灣牛樟芝搶進國際市場

Insumate®專利定序19肽 代謝醫學再突破 醫學中心臨床試驗:可輔助糖尿病治療

綠茵固態發酵牛樟芝菌絲體與專利定序19肽獲美國匹茲堡發明展肯定

綠茵生技固態培養牛樟芝菌絲體獲國際發明展金牌

綠茵生技奪專利苦瓜萃取(含胜肽)日內瓦國際發明展金牌

Greenyn Biotechnology Receives the 'Potential Benchmark Award' at the 2021 Taiwan BIO Awards. On November 4th, at the physical exhibition of 'BIO Asia-Taiwan 2021', the award was presented by former Vice President Academician Chen Chien-jen, recognizing Greenyn Biotechnology for its research and development capabilities, future potential, and significant contributions to the advancement of the biotechnology industry and economic development in Taiwan.